Clinical evaluation of novel markers in the diagnosis of anemia.

Clinical evaluation of novel markers in the diagnosis of anemia. - Clinical evaluation of novel markers in the diagnosis of anemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON41145

Enrollment

300

Registered

2014-10-21

Start date

2014-11-10

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anemia iron-deficiency

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: referral by general practitioner (or other specialist) for analysis of anemia referral by general practitioner (or other specialist) for analysis of exhaustion age 18 or above

Exclusion criteria

Exclusion criteria: Age below 18

Design outcomes

Primary

Measure	Time frame
- Time from baseline until first classification of anemia (iron-deficiency, anemia of chronic disease, other) - Time from baseline until definitive diagnosis (stomach ulcer, colon carcinoma, kidney failure, hematologic malignancy etc.) - Time from baseline until start of therapy if applicable (f.e. iron suppletion) - Therapy response: absolute Hb-increase 8 and 16 weeks from baseline - Therapy response: percentage of required Hb-increase compared to baseline - Therapy response: Delta values of anemia markers (MCV, ferritine, RET-HE, sTfR, sTfR/log(ferritin), Reticulocytes, RPI, transferrin/log(ferritin)) at 16 weeks from baseline. - Percentage of patients with normalization of Hb-lever at 16 weeks from baseline (Hb>7.5 and >8.5 mmol/L for women and men respectively) - Shifts in the Thomas plat subsequent to therapy	—

Measure

Time frame

- Time from baseline until first classification of anemia (iron-deficiency, anemia of chronic disease, other) - Time from baseline until definitive diagnosis (stomach ulcer, colon carcinoma, kidney failure, hematologic malignancy etc.) - Time from baseline until start of therapy if applicable (f.e. iron suppletion) - Therapy response: absolute Hb-increase 8 and 16 weeks from baseline - Therapy response: percentage of required Hb-increase compared to baseline - Therapy response: Delta values of anemia markers (MCV, ferritine, RET-HE, sTfR, sTfR/log(ferritin), Reticulocytes, RPI, transferrin/log(ferritin)) at 16 weeks from baseline. - Percentage of patients with normalization of Hb-lever at 16 weeks from baseline (Hb>7.5 and >8.5 mmol/L for women and men respectively) - Shifts in the Thomas plat subsequent to therapy

—

Countries

Netherlands

Outcome results